2012 Annual Shareholder Meeting Presentation
•
2 likes•415 views
Chairman Lloyd Dean and CEO Chris Calhoun present at the Annual Meeting of Shareholders on August 16, 2012
Recommended
More Related Content
Viewers also liked
Viewers also liked (19)
Similar to 2012 Annual Shareholder Meeting Presentation
Similar to 2012 Annual Shareholder Meeting Presentation (20)
More from Cytori Therapeutics, Inc.
More from Cytori Therapeutics, Inc. (19)
Recently uploaded
Recently uploaded (20)
2012 Annual Shareholder Meeting Presentation
- 1. Cytori Therapeutics, Inc. Annual Shareholder Meeting August 16, 2012 9:00 AM PT
- 2. Safe Harbor Statement This presentation may contain certain ‘forward-looking statements’. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation are also subject to a number of material risks and uncertainties. We caution investors not to place undue reliance on the forward-looking statements contained in this presentation. We would advise reading our annual report filed with the United States Securities and Exchange Commission on Form 10-K for a more detailed description of these risks.
- 3. Our Company Mission To improve the quality and length of life by providing innovative cell therapy products CYTORI - The Leader in Cell Therapy
- 4. Lesley’s Story Pre-TreatmentAdjunct to Burn Resurfacing Pre-Treatment
- 5. Lesley’s Story Pre-Treatment 3 Weeks Post Treatment 8 Weeks Post Treatment 20 Weeks Post Treatment
- 6. Lesley’s Story Pre-Treatment Burn Scar Repair 18 Months Pre-Treatment
- 7. Lesley’s Story Pre-Treatment Burn Scar Repair Before 18 Months Pre-Treatment
- 8. Lesley’s Story Pre-Treatment 12 Month Post Op 18 Month Post Op
- 9. Easy to Access Cells A small amount of fat is removed (about half a can of coke)
- 10. Point-of-Care Your tissue is processed right at the side of your bed
- 11. About an hour … And available when you need it
- 12. The Power of Cell Therapy > 5,000 patients have been treated using their own cells with Cytori products
- 13. Clinical Leadership > 5,000 Patients Treated (est.) 1% 2% 5% Breast Recon 1% 11% 5 Clinical Trials • 3 Complete (2 CV, 1 Breast) Breast • 2 Ongoing (2 CV) Augmentation 27% • Others planned Other Fat Grafting Cardiac 40+ Investigator Studies 53% Urology
- 14. Cytori Product Families >5,000 patients treated >8,600 patients treated Available in 47 countries Available in 52 countries Available globally
- 15. Momentum is Building Expanded soft tissue claims Recurring revenues increasing Preparing for vascular market Demand for cell & tissue banking is increasing
- 16. Advance Pipeline toward Market Access Preclinical Research Phase I/II Pivotal Full Market Access Private Pay/ Reimbursement Breast /Buttock Face Augmentation Breast Cancer Reconstruction Soft Tissue Facial Wasting Diabetic Foot Ulcers Fistula Burns Radiation Induced Injury SUI Sports Related Injury Heart Failure / No Option Chronic Myocardial Ischemia Acute Myocardial Infarction Critical Limb Ischemia Puregraft Banking
- 17. Refractory Heart Failure ATHENA TRIAL • FDA Approved Multicenter Trial • Double Blind, Placebo controlled • 45 Patients: 30 ADRC, 15 Placebo • 6 Leading US Cardiac Cell Therapy Centers Dr. Perin, Dr. Willerson, Texas Heart Dr. Henry, Minneapolis Heart Dr. Miller, University South Florida Dr. Pepine, University of Florida, Gainsville Dr. Mendelsohn, Cardiology PC, Alabama Dr. Schatz, Scripps La Jolla, California Emerson Perin, MD Texas Heart Institute
- 18. Acute Heart Attack ADVANCE TRIAL • European Pivotal Trial • Prospective • Randomized (2:1) • Double Blind • Placebo controlled • Up to 216 patients for STEMI • Enrollment to begin in Q4 ’12 • G5 • The Netherlands • Canada • Poland Eric Duckers, MD, PhD Rotterdam, The Netherlands
- 19. Intellectual Property • 51 Patents + 2 Allowances • 75+ Applications in process • ~50% growth in portfolio • Avg 1 patent / month
- 20. Shareholder Value • Advance pipeline toward Market Access • Manage to cash flow positive Grow revenue Control costs • Strengthen balance sheet
- 21. Milestones Achieved in 2012 FDA approval to initiate ATHENA CE Mark for wounds, burns, radiation, ischemia Additional country approvals (Russia, Croatia) Breast Reconstruction Reimbursement filing - UK Publish 6 & 18 month data: APOLLO Publish 12 month data: RESTORE 2 Puregraft 850 FDA & CE Mark, PG250 approvals Grow IP Portfolio > 15%
- 22. Milestones • Establish Strategic Partnership • Initiate ATHENA Trial – US (First patient enrolled) • Cardiovascular CE Mark expansion • Additional country approvals (Canada, Australia, New Zealand, Japan) • FDA Appeal Resolution • Publish 18 month data – PRECISE Trial • Revenue growth target of $9 million
- 23. Vision Cells concentrated from a person’s own fat tissue, will be used to treat a broad array of diseases in patients around the world MISSION: To improve the quality and length of life by providing innovative cell therapy products
- 24. Cytori is… Defining the market for point- of-care cell therapy Delivering on the promise in cell therapy Leading in delivering cell therapy to doctors & patients MISSION: To improve the quality and length of life by providing innovative cell therapy products
- 25. Thank You ! Cytori: Restoring Lives